VEGF-Trap decreases CD4+ T cells, Th17 cytokines improving psoriasis-like skin inflammation in KC-Tie2 mice

Journal of Dermatological Science

Volumn 72, Issue 3, 2013, Pages 322-325

  Diaconu, Doina ^a   Fritz, Yi ^a   Dawes, Sean M ^a   Loyd, Candace M ^a   Ward, Nicole L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; CALGRANULIN A; CALGRANULIN B; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1ALPHA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6;

ACANTHOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DERMATITIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HALF LIFE; INNATE IMMUNITY; LETTER; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; TH17 CELL; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MICE; PSORIASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TH17 CELLS;

EID: 84887162797     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.08.005     Document Type: Letter

References (9)

1. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
2. Kunstfeld R., Hirakawa S., Hong Y.K., Schacht V., Lange-Asschenfeldt B., Velasco P., et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004, 104:1048-1057.
3. Jung K., Lee D., Lim H.S., Lee S.-I., Kim Y.J., Lee G.M., et al. Double anti-angiogenic and anti-inflammatory protein valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem 2011, 286:14410-14418.
4. Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D., Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003, 102:161-168.
5. Akman A., Yilmaz E., Mutlu H., Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 2009, 34:e202-e204.
6. Fournier C., Tisman G. Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J 2010, 16(17.).
7. Wolfram J.A., Diaconu D., Hatala D.A., Rastegar J., Knutsen D.A., Lowther A., et al. Keratinocyte but not endothelial cell specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol 2009, 174:1443-1458.
8. Ward N.L., Loyd C.M., Wolfram J.A., Diaconu D., Michaels C.M., McCormick T.S. Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Brit J Dermatol 2011, 164:750-758.
9. Schonthaler H.B., Huggenberger R., Wculek S.K., Detmar M., Wagner E.F. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009, 21264-21269.